Navigation Links
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Date:1/8/2008

SAN CARLOS, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the start of its Phase 2 study for NKTR-118 (PEG-naloxol), an oral treatment being developed to treat opioid-induced constipation (OIC) and other clinical manifestations of opioid-induced bowel dysfunction (OBD). The double-blind, randomized, dose-escalation trial will evaluate the efficacy, safety and tolerability of NKTR-118 in patients experiencing constipation while receiving opioid therapy.

"We are excited to begin our Phase 2 clinical trial for oral NKTR-118 in OBD and OIC patient settings," said Hoyoung Huh, M.D., Ph.D. Chief Operating Officer and Head of the PEGylation Business Unit at Nektar. "NKTR-118 represents an innovative application of our small molecule PEGylation technology to prevent drugs from entering the central nervous system."

NKTR-118 is being evaluated as an oral therapy to treat OBD and OIC, which are serious and debilitating conditions resulting from the use of opioids for pain management. NKTR-118, which is a PEGylated form of naloxol, was designed to selectively target peripheral opioid receptors to alleviate constipation associated with opioid therapy, while reducing the drug's penetration across the blood-brain barrier (BBB) and into the central nervous system in order to preserve opioid analgesia.

About the Phase 2 Clinical Development Program for NKTR-118 (oral PEG-naloxol)

The Phase 2 trial for NKTR-118 is a multi-center, placebo-controlled, dose-escalation trial (5 mg, 25 mg, 50 mg or 100 mg). Patients experiencing OIC will be randomized 1:1 to NKTR-118 or placebo in addition to their opioid treatment. Therapy will be administered orally once-daily (QD) over a five-week trea
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
11. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ... today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") ... 2014. The terms of the acquisition were not disclosed. ... ("DME") company providing a wide range of sleep, mobility, and ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... New Jersey, October 7, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ZMH and SIX: ZMH) announced today its ... broadcast live over the Internet on Thursday, Oct. 28, 2010, ... quarterly results will be made available at 7:00 a.m. Eastern ... The live audio webcast can be accessed via Zimmer,s Investor ...
Cached Medicine Technology:International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 2International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 3International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 4International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 5International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 6International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 7International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 8Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2010 Results 2
(Date:4/18/2014)... being prepped to enter the battle against infectious ... diseases in remote areas, thanks in part to ... the International Space Station on the behavior of ... capillary flow to diagnose infectious diseases such as ... researcher at Northwestern University in Evanston, Ill., had ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... MDTH ) announced that its senior management will give ... January,7 - 10, 2008 at the Westin St. Francis ... give its presentation on Thursday,January 10, 2008 at 10:00 ... the Internet via MedCath,s website (http://www.medcath.com ) and,will ...
... Show with, Fashions by Chloe Dao, Presented by Rachel Hunter, Benefiting Dress ... ... Culminating a year of,empowering women to ,find their slim, and supporting the ... with the Style Your Slim(SM) Fashion Show in Los Angeles, CA, on,January 8th. ...
... SOUTH WINDSOR, Conn., Jan. 2 Gerber,Scientific, Inc. (NYSE: ... announced that Marc T. Giles, President and Chief Executive,Officer, ... Conference,being held in New York on Tuesday, January 8, ... of the presentation will be available on the home ...
... of Aetna, Inc., LOVELAND, Colo., Jan. 2 ... that Ms. Louise McCormick has joined the,company,s Board ... "We pride ourselves on our commitment to excellence ... quality, independent Directors,is critical to this effort," said ...
... finds whites are prescribed opioids more often than blacks, Hispanics ... in an emergency room in significant pain, you are less ... if you are not white, new research shows. , The ... that minorities don,t get effective pain treatment in the ER ...
... benefits outweigh its risks , , WEDNESDAY, Jan. 2 (HealthDay ... cause high blood pressure in patients with kidney cancer, ... of a study published last month that found the ... failure among patients with stomach cancer. , "Patients taking ...
Cached Medicine News:Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 2Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 3Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 4Health News:Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3Health News:Minorities Less Likely to Get Powerful Painkillers in ER 2Health News:Minorities Less Likely to Get Powerful Painkillers in ER 3Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Medicine Products: